Volume 72, Issue 12, Pages (December 2007)

Slides:

Advertisements

Similar presentations

An alcoholic patient with recurrent renal failure and proteinuria T. Kumagai, Y. Hori, G. Seki, Toshiro Fujita Kidney International Volume 70, Issue 8,

Advertisements

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Volume 54, Pages S135-S139 (December 1998)

A.M. Thompson, T.G. Pickering Kidney International

V.M. Campese, N. Mitra, D. Sandee Kidney International

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Beta blockers in the management of chronic kidney disease

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Membranous nephropathy: When and how to treat

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007 Joanna M. Smith, Susan A. Mott,

Progression of renal failure and hypertensive nephrosclerosis

Volume 69, Issue 7, Pages (April 2006)

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Volume 70, Pages S21-S25 (December 2006)

V.M. Campese, N. Mitra, D. Sandee Kidney International

Volume 90, Issue 3, Pages (September 2016)

Homocysteine and risk in end-stage renal disease: a matter of context

Volume 69, Issue 2, Pages (January 2006)

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

Comorbidity and confounding in end-stage renal disease

A new era in phosphate binder therapy: What are the options?

Proinflammatory effects of iron sucrose in chronic kidney disease

Volume 74, Issue 3, Pages (August 2008)

Volume 80, Issue 10, Pages (November 2011)

Volume 70, Issue 11, Pages (December 2006)

Volume 72, Issue 12, Pages (December 2007)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Volume 70, Issue 12, Pages (December 2006)

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S. Bianchi, R. Bigazzi, V.M. Campese

Volume 71, Issue 6, Pages (March 2007)

Volume 70, Issue 12, Pages (December 2006)

Elke Wühl, Otto Mehls, Franz Schaefer Kidney International

Blood pressure targets in hemodialysis patients

Volume 69, Issue 10, Pages (May 2006)

Fructose intake as a risk factor for kidney stone disease

Recent experience with high-dose intravenous iron administration

The third World Kidney Day: Looking back and thinking forward

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Proteinuria and hypertensive nephrosclerosis in African Americans

Methods for guideline development

Environmental exposure to lead and progressive diabetic nephropathy in patients with type II diabetes J.-L. Lin, D.-T. Lin-Tan, C.-C. Yu, Y.-J. Li, Y.-Y.

The global challenge of chronic kidney disease

Volume 73, Issue 7, Pages (April 2008)

Volume 54, Pages S135-S139 (December 1998)

Volume 71, Issue 9, Pages (May 2007)

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Volume 73, Issue 5, Pages (March 2008)

Organ transplantation goes to the movies

Volume 72, Issue 2, Pages (July 2007)

Volume 70, Issue 7, Pages (October 2006)

Volume 80, Issue 10, Pages (November 2011)

Is it the low-protein diet or simply the salt restriction?

Volume 75, Issue 1, Pages (January 2009)

Volume 70, Issue 3, Pages (August 2006)

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.

Volume 71, Issue 9, Pages (May 2007)

Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate S. Aime, C. Canavese, P. Stratta Kidney International

Volume 70, Issue 5, Pages (September 2006)

Mild renal insufficiency is associated with reduced coronary flow in patients with non- obstructive coronary artery disease A.R. Chade, D. Brosh, S.T.

H.J. Chin, H. Ro, H.J. Lee, K.Y. Na, D.-W. Chae Kidney International

Comparison of antioxidant activity of cilnidipine and amlodipine

Volume 72, Issue 11, Pages (December 2007)

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Volume 69, Issue 8, Pages (April 2006)

In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression B.O. Eriksen, O.C. Ingebretsen Kidney.

Volume 72, Issue 12, (December 2007)

Quantitative estimation of renal blood flow by power Doppler ultrasonography in renovascular hypertensive dogs Tetsumasa Miyajima, Hiroshi Yokoyama,

Antonio Piccoli, Luana Pillon Kidney International

Presentation transcript:

Volume 72, Issue 12, Pages 1543-1549 (December 2007) Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin- angiotensin inhibition in hypertensive patients with chronic renal disease T. Fujita, K. Ando, H. Nishimura, T. Ideura, G. Yasuda, M. Isshiki, K. Takahashi Kidney International Volume 72, Issue 12, Pages 1543-1549 (December 2007) DOI: 10.1038/sj.ki.5002623 Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 1 Flow of participants throughout the study. Kidney International 2007 72, 1543-1549DOI: (10.1038/sj.ki.5002623) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 2 Changes in systolic and diastolic BP. BP was almost the same in the cilnidipine (closed circles) and the amlodipine (open circles) groups except for a slight difference in systolic BP at one point. *P<0.05, cilnidipine vs amlodipine groups. Kidney International 2007 72, 1543-1549DOI: (10.1038/sj.ki.5002623) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 3 Changes in urinary protein/Cr ratio during the treatment period. Results are expressed as the mean±s.e.m. The urinary protein/Cr ratio was suppressed in the cilnidipine group but not in the amlodipine group. *P<0.05, †P<0.01, cilnidipine vs amlodipine groups. Kidney International 2007 72, 1543-1549DOI: (10.1038/sj.ki.5002623) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 4 Changes in urinary protein/Cr ratio in subgroups with different baseline urinary protein/Cr ratio, age, sex, BP after 12 months of treatment, or etiology of kidney disease. Results are expressed as the mean±s.e.m. The antiproteinuric effect was superior in the cilnidipine group compared with the amlodipine group even in the different subgroups. Kidney International 2007 72, 1543-1549DOI: (10.1038/sj.ki.5002623) Copyright © 2007 International Society of Nephrology Terms and Conditions